Recently, Novartis filed injunctions against half a dozen companies to prevent them from launching generic versions of its blockbuster anti-diabetic drug, Galvus (vildagliptin).
Friday, 2 May 2014
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment